PRODUCT MONOGRAPH

Pr MAR-METHIMAZOLE

Methimazole Tablets USP
5 mg and 10 mg

Antithyroid Agent

Marcan Pharmaceuticals Inc.
2 Gurdwara Road, Suite # 112
Ottawa, ON, K2E 1A2

Date of Revision:
August 14, 2018

Control # 211048
### Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION .......................................................... 3
- SUMMARY OF PRODUCT INFORMATION ............................................................. 3
- INDICATIONS AND CLINICAL USE ......................................................................... 3
- CONTRAINDICATIONS .............................................................................................. 3
- WARNINGS AND PRECAUTIONS ............................................................................. 4
- ADVERSE REACTIONS ............................................................................................... 6
- DRUG INTERACTIONS ............................................................................................... 6
- OVERDOSAGE ............................................................................................................. 7
- STORAGE AND STABILITY ....................................................................................... 8
- DOSAGE FORMS, COMPOSITION AND PACKAGING .......................................... 9

PART II: SCIENTIFIC INFORMATION ........................................................................ 10
- PHARMACEUTICAL INFORMATION ..................................................................... 10

PART III: CONSUMER INFORMATION ..................................................................... 11
Pr MAR-METHIMAZOLE
Methimazole Tablets USP
5 mg and 10 mg

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY OF PRODUCT INFORMATION

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Dosage Form / Strength</th>
<th>Clinically Relevant Non-medicinal Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td>Tablet 5 mg and 10 mg</td>
<td>lactose monohydrate, magnesium stearate, starch and talc.</td>
</tr>
</tbody>
</table>

INDICATIONS AND CLINICAL USE

- MAR-METHIMAZOLE (methimazole) is indicated in the medical treatment of hyperthyroidism. Long-term therapy may lead to remission of the disease.
- MAR-METHIMAZOLE may be used to ameliorate hyperthyroidism in preparation for subtotal thyroidectomy or radioactive iodine therapy.
- MAR-METHIMAZOLE is also used when thyroidectomy is contraindicated or not advisable.

CONTRAINDICATIONS

- Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see the Dosage Forms, Composition and Packaging section of the product monograph.
- Nursing mothers, as the drug is excreted in breast milk.
WARNINGS AND PRECAUTIONS

**Serious Warning and Precautions**

Agranulocytosis (see Hematologic section below)

Liver toxicity (see Hepatic/Biliary/Pancreatic section below)

**General**

Patients who receive methimazole should be under close surveillance. Physicians should encourage patients to immediately report any evidence of illness or unusual clinical symptoms, particularly sore throat, skin eruptions, fever, headache or general malaise. In such cases, white blood cell and differential counts should be made to determine whether agranulocytosis has developed. Particular care should be exercised with patients who are receiving additional drugs known to cause agranulocytosis.

The development of arthralgias should prompt drug discontinuation, since this symptom may indicate a severe transient migratory polyarthritis known as “the antithyroid arthritis syndrome”.

**Carcinogenesis and Mutagenesis**

Rats treated for 2 years with methimazole demonstrated thyroid hyperplasia and thyroid adenoma and carcinoma formation. Such findings are seen with continuous suppression of thyroid function by sufficient doses of a variety of antithyroid agents. Pituitary adenomas have also been observed.

**Endocrine and Metabolism**

**Lactose**

Methimazole tablets contain lactose monohydrate. Patients with hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this product.

**Hematologic**

Agranulocytosis is potentially the most serious side effect of therapy with methimazole. Patients should be instructed to report to their physicians any symptoms of agranulocytosis, such as fever or sore throat. Leukopenia, thrombocytopenia, and aplastic anemia (pancytopenia) may also occur. The drug should be discontinued in the presence of agranulocytosis or plastic anemia (pancytopenia). The patient’s bone marrow function should be monitored. See Monitoring and Laboratory Tests.

**Anticoagulant Therapy**

Treating patients with both methimazole and warfarin necessitates intensive and frequent
monitoring, in particular when initiating, discontinuing or changing doses of methimazole, since alterations in the thyroid function affect the response to anticoagulation. See Drug-Drug Interactions.

**Hepatic/Biliary/Pancreatic**

Due to the similar hepatic toxicity profiles of methimazole and propylthiouracil, attention is drawn to the severe hepatic reactions, which have occurred with both drugs. There have been rare reports of fulminant hepatitis, hepatic necrosis, encephalopathy and death. Cholestatic jaundice has occurred rarely. Patients should be instructed to report symptoms of hepatic dysfunction such as jaundice, anorexia, pruritus, and/or right upper-quadrant pain. Their presence should prompt evaluation of liver function tests and discontinuation of methimazole. Drug treatment should be discontinued promptly in the event of clinically significant evidence of liver abnormality, including hepatic transaminase values exceeding 3 times the upper limit of normal. See Monitoring and Laboratory Tests.

**Skin**

The drug should be discontinued in the presence of exfoliative dermatitis.

**Special Populations**

**Pregnant Women:** Methimazole can cause fetal harm when administered to a pregnant woman. Methimazole readily crosses the placental membranes and can induce goiter and even cretinism in the developing fetus. In addition, rare instances of aplasia cutis, as manifested by scalp defects have occurred in infants born to mothers who received methimazole during pregnancy. If methimazole is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be warned of the potential hazard to the fetus.

Since scalp defects have not been reported in offspring of patients treated with propylthiouracil, this agent may be preferable to methimazole in pregnant women requiring treatment with antithyroid drugs.

Methimazole used judiciously is an effective drug in the treatment of hyperthyroidism complicated by pregnancy. In many pregnant women, the thyroid dysfunction diminishes as the pregnancy proceeds; consequently, a reduction in dosage may be possible. In some instances, use of methimazole can be discontinued 2 or 3 weeks before delivery.

**Nursing Women:** Methimazole is excreted in human breast milk and its use is contraindicated in nursing mothers.

**Pediatrics:** No formal studies have been conducted in the pediatric population.

**Geriatrics:** No formal studies have been conducted in the geriatric population.
**Monitoring and Laboratory Tests**

The patient’s liver function, hepatic transaminase levels, and the complete blood count should be closely monitored. See **Boxed Warning** and **Hematologic** section above. Because methimazole may cause hypoprothrombinemia and bleeding, prothrombin time/INR should also be monitored during therapy with the drug, especially before surgical procedures.

Periodic monitoring of thyroid function is warranted. A laboratory result indicating elevated TSH warrants a decrease in the dosage of methimazole.

**ADVERSE REACTIONS**

**Adverse Drug Reaction Overview**

Adverse reactions occur in less than 1 percent of patients.

Serious adverse reactions (which occur less frequently than the minor less serious adverse reactions) include inhibition of myelopoiesis (agranulocytosis, granulocytopenia and thrombocytopenia), aplastic anemia, drug fever, a lupus-like syndrome, insulin autoimmune syndrome (which can result in hypoglycemic coma), hepatitis (jaundice may persist for several weeks after discontinuation of the drug), periarteritis and hypoprothrombinemia. Nephritis occurs very rarely. Cholestatic jaundice, fulminant hepatitis, encephalopathy, hepatic necrosis and death have been rarely reported. (see **Warning and precautions** section)

Less serious adverse reactions include skin rash, urticaria, nausea, vomiting, epigastric distress, arthralgia, paresthesia, loss of taste, abnormal loss of hair, myalgia, headache, pruritus, drowsiness, neuritis, edema, vertigo, skin pigmentation, jaundice, sialadenopathy, anorexia, right upper-quadrant pain and lymphadenopathy.

**Abnormal Hematologic and Clinical Chemistry Findings**

It should be noted that about 10% of patients with untreated hyperthyroidism have leucopenia (white-blood-cell count of less than 4,000/mm³), often with relative granulopenia.

**DRUG INTERACTIONS**

**Drug-Drug Interactions:**

Increases and decreases in warfarin-induced anticoagulation have been reported in patients taking methimazole. In hyperthyroid patients, the metabolism of vitamin K clotting factors is increased, resulting in increased sensitivity to oral anticoagulants. Antithyroid drugs, by reducing the extent of hyperthyroidism, decrease the metabolism of clotting factors and thus reduce the effects of oral anticoagulants. On the other hand, patients on anticoagulant therapy who are euthyroid due to antithyroid agents may develop marked hypoprothrombinemia if the antithyroid medications are ceased and they become thyrotoxic again. Treating patients with both methimazole and warfarin necessitates intensive and frequent monitoring, in particular
when initiating, discontinuing or changing doses of methimazole, since alterations in thyroid function affect the response to anticoagulation.

**Drug-Food Interactions**

Interactions with foods have not been studied.

**Drug-Herb Interactions**

Interactions with herbal products have not been studied.

**Drug-Laboratory Test Interactions**

Interactions with laboratory tests have not been studied.

**DOSAGE AND ADMINISTRATION**

**Dosing Considerations**

- Methimazole is administered orally.
- It is usually given in three equal doses a day at approximately eight-hour intervals.
- Patients should wash their hands with soap and water after handling the tablet, particularly if they have to break the tablet.
- Methimazole should not be handled by pregnant women and children.

**Recommended Dose and Dosage Adjustment**

**Adult:** The initial daily dose is 15 mg for mild hyperthyroidism, 30 to 40 mg for moderately severe hyperthyroidism and 60 mg for severe hyperthyroidism, divided into three doses at eight-hour intervals. The maintenance dosage is 5 to 15 mg daily.

**Pediatric:** Initially, the daily dosage is 0.4 mg/kg of body weight divided into three doses and given at eight-hour intervals. The maintenance dosage is approximately ½ of the initial dose.

**Missed Dose**

No data is available.

**OVERDOSAGE**

For management of suspected drug overdose, contact your regional Poison Control Centre Immediately.

**Symptoms:** Symptoms may include nausea, vomiting, epigastric distress, headache, fever, joint pain, pruritus and edema. Aplastic anemia (pancytopenia) or agranulocytosis may be manifested in hours to days. Less frequent events are hepatitis, nephrotic syndrome, exfoliative dermatitis, neuropathies and CNS stimulation or depression. Although not well studied, methimazole-induced agranulocytosis is generally associated with doses of 40 mg or more in patients older than 40 years of age.
No information is available on the median lethal dose of the drug or the concentration of methimazole in biologic fluids associated with toxicity and/or death.

**Treatment:** In managing overdosage, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics in your patient.

Protect the patient’s airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient’s vital signs, blood gases, serum electrolytes, etc. The patient’s bone marrow function should be monitored. Absorption of drugs from the gastrointestinal tract may be decreased by giving activated charcoal, which, in many cases, is more effective than emesis or lavage; consider charcoal instead of or in addition to gastric emptying. Repeated doses of charcoal over time may hasten elimination of some drugs that have been absorbed. Safeguard the patient’s airway when employing gastric emptying or charcoal.

Forced diuresis, peritoneal dialysis, hemodialysis or charcoal hemoperfusion have not been established as beneficial for an overdose of methimazole.

**ACTION AND CLINICAL PHARMACOLOGY**

**Mechanism of Action**

Methimazole inhibits the synthesis of thyroid hormones and thus is effective in the treatment of hyperthyroidism. The drug does not inactivate existing thyroxine and triiodo-thyroxine that are stored in the thyroid or circulating in the blood, nor does it interfere with the effectiveness of thyroid hormones given by mouth or by injection.

The actions and use of methimazole are similar to those of propylthiouracil. On a weight basis, the drug is at least ten times as potent as propylthiouracil, but methimazole may be less consistent in action.

**Pharmacokinetics**

**Absorption:** Methimazole is readily absorbed from the gastrointestinal tract.

**Metabolism:** It is metabolized rapidly and requires frequent administration.

**Excretion:** Methimazole is excreted in the urine.

**STORAGE AND STABILITY**

Store at room temperature (15 to 30 °C). Protect from light. Keep tightly closed.
DOSAGE FORMS, COMPOSITION AND PACKAGING

MAR-METHIMAZOLE 5 mg tablets:
Round white to off white bi-convex tablet. Debossed HP bisect 70 on one side and plain on reverse side.

Available in bottles of 100.

MAR-METHIMAZOLE 10 mg tablets:
Round white to off white bi-convex tablet. Debossed HP bisect 71 on one side and plain on reverse side

Available in bottles of 100.

Non-medicinal ingredients: lactose monohydrate, magnesium stearate, starch and talc.
PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Proper name: Methimazole / Thiamazole
Chemical name: 2H-Imidazole-2-thione
Molecular formula and molecular mass: C₄H₆N₂S
114.2 g / mol

Structural formula:

![Structural formula of Methimazole](image)

Physicochemical properties:

**Description:** White to pale buff crystalline powder with a characteristic odour. It differs chemically from the drugs of the thiouracil series primarily because it has a five- instead of a six-membered ring.

**Melting range:** 143 - 146°C

**Solubility:** Freely soluble in water, alcohol and in acetone
CLINICAL TRIALS

Bioequivalence summary:

A randomized, double-blind, balanced, two-treatment, two-period, two-sequence, single dose, two-way crossover, bioequivalence study of Mar-Methimazole (Methimazole) 10 mg tablets (Marcan Pharmaceuticals Inc.) with PrTAPAZOLE® (Methimazole) 10 mg tablets (Paladin Labs Inc.) in 34 healthy, adult, human male subjects, under fasting conditions.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Test*</th>
<th>Reference †</th>
<th>% Ratio of Geometric Means</th>
<th>90% Confidence Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUCT</td>
<td>1925.58</td>
<td>1915.94</td>
<td>100.50</td>
<td>97.97 – 103.11</td>
</tr>
<tr>
<td>(ng.h/mL)</td>
<td>1952.39 (16.85)</td>
<td>1944.09 (17.65)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AUCI</td>
<td>2163.70</td>
<td>2157.42</td>
<td>100.29</td>
<td>97.29 – 103.38</td>
</tr>
<tr>
<td>(ng.h/mL)</td>
<td>2201.02 (18.90)</td>
<td>2200.10 (20.67)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cmax</td>
<td>274.57</td>
<td>292.92</td>
<td>93.74</td>
<td>86.26 – 101.86</td>
</tr>
<tr>
<td>(ng/mL)</td>
<td>282.06 (23.44)</td>
<td>300.08 (22.52)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tmax</td>
<td>0.50</td>
<td>0.50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(h)</td>
<td>(0.17-1.50)</td>
<td>(0.33-1.50)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T½</td>
<td>7.62 (15.65)</td>
<td>7.75 (21.43)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Mar-Methimazole 10 mg tablets; Manufactured by Marcan Pharmaceuticals Inc., Ottawa, Canada
† PrTapazole (Methimazole 10 mg tablets); Manufactured by Paladin Labs Inc., Canada, was purchased in Canada.
§ Expressed as the median (range) only
€ Expressed as the arithmetic mean (CV%) only

DETAILED PHARMACOLOGY

No data is available.

TOXICOLOGY

No data is available.

References:

1. Product Monograph Pr TAPAZOLE®, date of revision April 27, 2011; Paladin Labs Inc., Control Number 144476.
PART III: CONSUMER INFORMATION

\textit{MAR-METHIMAZOLE}
Methimazole Tablets USP

This leaflet is part III of a three-part "Product Monograph" published when Mar-Methimazole was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about Mar-Methimazole. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

What the medication is used for:
- MAR-METHIMAZOLE is used in the treatment of hyperthyroidism (overactive thyroid gland).
- MAR-METHIMAZOLE is used for treating and preparing the overactive thyroid gland for surgical removal or for radioactive iodine treatment.
- MAR-METHIMAZOLE is also used when the overactive thyroid gland cannot be removed.

What it does:
- Mar-Methimazole inhibits the synthesis (production) of thyroid hormones.
- The drug does not affect the levels of the thyroid hormones that are already present in the thyroid gland or are circulating in the blood.

When it should not be used:
- If you are hypersensitive (allergic) to methimazole or any of the ingredients in Mar-Methimazole.
- If you are breastfeeding.

What the medicinal ingredient is:
Methimazole

What the important nonmedicinal ingredients are:
lactose monohydrate, starch, magnesium stearate and talc.

What dosage form it comes in:
5 mg and 10 mg tablets.

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions
Possible serious side effects include:
- agranulocytosis (a marked decrease in white blood cell counts)
- liver toxicity

BEFORE you use MAR-METHIMAZOLE talk to your doctor or pharmacist if:
- you have a low white blood cell count
- you have joint pain. MAR-METHIMAZOLE may result in antithyroid arthritis syndrome
- you have liver disease
- you have a skin disease
- you are intolerant to milk sugar. MAR-METHIMAZOLE contains a milk sugar (lactose).
- you are pregnant or planning to become pregnant
- you are breast feeding or planning to breastfeed

INTERACTIONS WITH THIS MEDICATION

Drugs that may interact with MAR-METHIMAZOLE include: anticoagulants (blood thinning drugs)
Talk to your doctor or pharmacist if you are taking any other medicine, prescription or non-prescription

PROPER USE OF THIS MEDICATION

You should follow the dose and directions given by your doctor.
MAR-METHIMAZOLE daily dose should be divided into the three equal doses, taken orally every 8 hours.

Patients should wash their hands with soap and water after handling the tablet, particularly if they have to break the tablet.

Methimazole should not be handled by pregnant women and children.

Usual Adult dose:
Initial daily dose:
15 mg for mild hyperthyroidism
30 mg to 40 mg for moderately severe hyperthyroidism
60 mg for severe hyperthyroidism

Maintenance daily dose: 5 mg to 15 mg

Usual children dose:
Initial daily dose: 0.4 mg/kg of body weight
Maintenance daily dose: approximately ½ the initial dose.

Overdosage
Symptoms may include nausea, vomiting, stomach discomfort, headache, fever, joint pain, rash and edema (fluid retention or swelling).

If you think you have taken too much MAR-METHIMAZOLE, contact your healthcare professional, hospital emergency department or regional poison control centre immediately, even if there are no symptoms.

Missed dose:
Talk to your doctor or pharmacist if you miss one of your scheduled doses of Mar-Methimazole.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Common side effects are:
- skin rash, hives (urticaria), itching, skin pigmentation
- nausea, vomiting, heart burn, loss of taste, anorexia (eating disorder)
- joint pain, muscle pain, numbness
- hair loss
- headache, drowsiness, dizziness
- neuritis (inflammation of a nerve, often with pain or tenderness), edema (swelling due to fluid build up)
- a disease of the lymph node (sialadenopathy and lymphadenopathy)

If you notice any side effects not mentioned above, or any above-mentioned side effects persist or become bothersome, please contact your doctor or pharmacist.
<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Talk with your doctor or pharmacist</th>
<th>Stop taking drug and call your doctor or pharmacist</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lower than normal numbers of red and white blood cells as well as platelets (Aplastic anaemia)</td>
<td>If effect persist or become bothersome</td>
<td>√ In all cases</td>
</tr>
<tr>
<td>Drug fever. Symptoms may include: fever greater than 105°F (40.5°C).</td>
<td>§</td>
<td></td>
</tr>
<tr>
<td>Local destruction of skin cells (Lupus-like syndrome). Symptoms may include: Rash especially when exposed to sun, fever, joint pain.</td>
<td>§</td>
<td></td>
</tr>
<tr>
<td>A syndrome where the body produces an immune response against its own cells (Insulin autoimmune syndrome). Symptoms may include: Numbness in the extremities, low levels of blood sugar.</td>
<td>§</td>
<td></td>
</tr>
<tr>
<td>Inflammation of the liver (Hepatitis). Symptoms may include: Jaundice, brownish or discoloured urine and abdominal pain.</td>
<td>§</td>
<td></td>
</tr>
<tr>
<td>Inflammation of the tissue surrounding an artery (Periarteritis). Symptoms may include: Pain in the muscles and joints.</td>
<td>§</td>
<td></td>
</tr>
<tr>
<td>Abnormally low levels of thrombin, a component of the Blood (Hypoprotebrinemia). Symptoms may include: Bleeding problems, easy bruising.</td>
<td>§</td>
<td></td>
</tr>
<tr>
<td>Inflammation of the kidney (Nephritis). Symptoms may include: Reduced urine, cloudy urine, blood in urine.</td>
<td>§</td>
<td></td>
</tr>
</tbody>
</table>

This is not a complete list of side effects. If you have any unexpected effects after receiving MAR-METHIMAZOLE, contact your doctor or pharmacist.

Talk to your doctor or pharmacist if these symptoms are persistent or severe

HOW TO STORE IT


Keep out of reach and sight of children.

REPORTING SIDE EFFECTS

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (http://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

If you want more information about MAR-METHIMAZOLE:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Consumer Information by visiting https://www.canada.ca/en/health-canada.html, Marcan Pharmaceuticals Inc.’s website www.marcanpharma.com, or by calling 1-855-627-2261.

This leaflet was prepared by Marcan Pharmaceuticals Inc.

Date of Revision: August 14, 2018.